Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection of relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction-based next-generation sequencing assay.
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse
Matteo Lambertini;
2022-01-01
Abstract
Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection of relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction-based next-generation sequencing assay.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cailleux F et al_JCO Precis Oncol 2022.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
753.78 kB
Formato
Adobe PDF
|
753.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
